1 / 45

ADAM Syndrome Androgen Deficiency in the Aging Man Andropause

ADAM Syndrome Androgen Deficiency in the Aging Man Andropause. “Is it not strange that desire should so many years outlive performance?” S hakespeare, W: Henry IV Part2. Norman Jensen MD MS Professor Emeritus UW Department of Medicine nmj@medicine.wisc.edu

alexavier-jacob
Download Presentation

ADAM Syndrome Androgen Deficiency in the Aging Man Andropause

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADAM SyndromeAndrogen Deficiency in the Aging ManAndropause “Is it not strange that desire should so many years outlive performance?”Shakespeare, W: Henry IV Part2. Norman Jensen MD MS Professor Emeritus UW Department of Medicine nmj@medicine.wisc.edu Primary Care Conference, March 28, 2007

  2. ILOsIntended Learning Outcomesa.k.a., Learning Objectives • Androgen physiology • Androgen changes with aging • Syndrome of ADAM • Effects of testosterone replacement • Practice guideline

  3. Literature Search • MESH Major: Hypogonadism 5,914 OR Testosterone 24,304 = 29,507 • Limits: • Human, Male, English, Adult 19+ = 5,267 • Last 10 years = 1930 • Core clinical journals = 454 • Randomized Clinical Trials = 115 • Reviews = 25 • Meta-analysis = 1 • Practice Guideline = 0 • Total = 141

  4. Testis, gross anatomy Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:479.

  5. Normal testicular volume > 15 ml. Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:486.

  6. Testis, micro anatomy Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:479.

  7. Testis, photomicrograph

  8. Hypothalamus – Pituitary – Testis Axis Aromatase → E2 5α reductase → DHT Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:483.

  9. DHEA = popular food supplement androgen Androgen metabolism Licorice Finasteride & dutasteride Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:481.

  10. Normal androgen sources Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:482.

  11. Normal androgen levels, serum Greenspan FS, Gardner DG. Basic & Clinical Endocrinology. Lange, NY, 2004:486.

  12. Mechanism of Action, T

  13. LH and Testosterone Excretion - Diurnal Rhythms Winters SJ. Diurnal rhythm of testosterone and LH in hypogonadal men. J Andrology 1991;12:185-190. (Pittsburgh)

  14. Ovarian hormone lifetime

  15. Testosterone in aging men

  16. Prevalence of Low T by Age NEJM 2004;350:483

  17. Clinical male hypogonadism NEJM 2004;350:483 USA Prevalence = 2-4 million ~ 5% on Rx

  18. Etiology, male hypogonadism Endocr Pract 2002;8:440-456

  19. Benefits of Testosterone replacement •  Sexual dysfunction •  Bone density & Lean muscle mass • Strength, endurance, falls •  Mood and cognition •  Erythropoesis • HIV-AIDS •  sense of well-being and muscle mass • Anti-inflammatory • Metabolic:  insulin resistance, A1c, visceral adiposity, total cholesterol, BP?, pre-diabetes

  20. Potential Harms of T • IoM concluded “no compelling evidence of major adverse side effects resulting from T therapy”. • “Prostate events” • BPH ( vol), LUTS, retention, CA • Obstructive sleep apnea • Erythrocytosis

  21. CardiovascularBenefits & Harms • No clinical trial evidence of either • However, lots of observational data •  Angiogram disease with lower T • Top 1/3 serum T = 0.2 age-adjusted relative risk • Mid 1/3 serum T = 0.4 •  exercise-free angina for men on T (Heart 2004;90:871-6) •  coronary artery diameter when injected directly with T • Men on T have  antithrombin III offsetting prothrombotic factors, prothrombinase, proteins C & S. • No effects on platelets. • No  in Cardiovascular events • No effect or  Tot cholesterol, LDL, HDL •  TNFα & IL1β and IL-10 Refs: Rhoden, NEJM 2004 / JCEM 2004;89:3313-18 / Heart2004;90:871-6.

  22. ErythropoesisBenefits & harms • Hgb  15-20 in boys at puberty • Men have higher Hgb than women • Hypogonad men have lower Hgb • Corrected by T replacement in 3 months • Risk of erythrocytosis (HCT > 52) •  with pulmonary insufficiency • dose related • No case reports of thromboembolism with T • Monitor Hgb or Hct

  23. Prostate DiseaseRisks and Benefits • No benefits observed •  P volume with Rx during first 6 months;  with castration (surgical or medical) • Risks of T Rx • No  LUTS or retention • Castration causes P cancer regression • No clinical trial evidence for  growth • Case reports only • P ca prevalent at age when T is declining

  24. Effects of T ReplacementJ Clin Edocrinol Metab 2000;85:2670-77 • Case series: 18 men > 18 y/o, hypoT due to organic disease (78+-77 ng/dl), never treated. Rx T transdermal 3 years. 16 completed 12 months, 14 all 36. • Results: Serum T normalized. L2-4 BMD  7.7%+-7.6(.001), fem trochanter BMD 4.0+--5.4%(.02) (both max 24 mos), lean body mass  3.1 kg (.004), HCT  38+-3% to 43.1+-4%(.002), prostate volume  12+-6 mL to 22.4+-8.4 mL (.004), energy  49+-19%66+-24% (.01), and sexual function 24+-20% to 66 +-24% (.001). Lipids did not change. • Full effect on BMD took 24 mos, all others 3-6 mos.

  25. Bone mineralJ Clin Edocrinol Metab 2002;87:3656-61 • Case-control study: 15 men 75y/o PCA & 17 normals 70y/o • 12 months after GnRh analog rx(chemical castration): • Total hip  3.3%, distal radius  5.3% (.001) • Spine  2.8% (ns), femoral neck  2.3% (ns) •  urine N-telopeptide (<.05) • (marker of bone resorption) • No bone loss in controls. • NEJM 2001;345:948-935 – bone loss with ADT prevented by pamidronate infusions. And alendronate (Osteoporosis International 2005;16:1591-96)

  26. Physical functioningJ Clin Endocrinol Metab 2005;90:1502-1510 • RCT: 70 T<350ng/dl, >64y/o to 200 mg / 2 wks vs. placebo X 36 months, 50 completed • Results: • Significant  timed function test*, handgrip strength (160%L & 900%R), & lean body mass, •  fat mass 17%, total cholesterol 19% & LDL 22% • NS trends in HDL -15% & fasting insulin -15%.

  27. Physical functioningEuropean J Endocrinology 2006;155:867-75. • RCT: n=70, 5 mg testoderm, placebo, exercise*, no exercise, 4 arms, 12 wks, 65-85 for SF36 and dual x-ray absorptiometry scan. • Results: T + Ex,  physical function (.03), role physical (.01), general health (.049), & social functioning (.04). • * home program, 11 resistive exercises, 10 each / day, 3-4 d/wk, using elastic bands, of various strengths, followed q2wk

  28. Metabolic Syndrome • Observations • T and insulin levels inversely related • Low T predict ins. res. and future DN • Men with DM more likely hypoT, ~33% • fT low in obese men, inversely :: BMI • HyopT have  abdom obesity • Obesity  T via aromatase conversion to E2 and via  leptin • Insulin  after GnRH agonist • Insulin & sugar levels  after castration • HypoT associated with HBP, dyslipid, & Metabolic Syndrome regardless of BMI

  29. Metabolic Syndrome • Experimental studies • Castrated rats show impaired insulin sensitivity corrected with physiologic T • Healthy men with low T improved insulin sensitivity and  insulin after T replacement • T rx  insulin resistance in obese men • T rx  TChol in hypoT men with CAD, even in those on statins • A report of improved A1c on T rx

  30. Metabolic SyndromeEuropean J Endocrinology, 2006;154:899-906 • Study, RCT, xo 3-1-3, 27 men age>30, hypoT and DM2, T200mg IMq2wk. • Results: • Insulin 14% (ns), FBS 6%(.03),  A1c 4%[.3](.03)TChol 5%(.03), %body fat 3%(ns),  waist circumference (.03),  waist:hip (.01) • No change in BMI, HDL, LDL, Trig, SysBP, DiaBP • Conclusion: T  insulin resistance & glycemia in hypogonad men with DM2 • Men with DM2 & met. Syndrome should be evaluated for hypogonadism. J Urol 2005;174:827-34 (review)

  31. CognitionAging Male 2003;6:13-18. • RCT (pilot): 10 men w new dx Alzheimer’s & hypoT (<240 ng/dl), 5 rx T 200 mg / 2wks & 5 placebo & tested at 3, 6, 9, 12 months. • RESULTS: MMSE  19.4 to 23.2 (.02) – comparable to ACH inhibitors. • Clock draw test  2.2 to 3.2 (.07) • Animal studies: T enhances ACH release,  nicotinic receptors, and affects Tau protein deposition. •  brain amyloid beta-peptide after GnRH analogs (e.g. Lupron) • Observed associations of T and memory

  32. Adverse EffectsofTestosteroneRx NEJM 2004;350:485

  33. Adverse EffectsofT Rx NEJM 2004;350:484

  34. Risk of Prostate Cancerqualitative review

  35. Calof OM, Singh AB, Martin LL, et.al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. Journal of Gerontology 2005;11:1451-1457. • 1966 – 4/2004: Testosterone (MESH), limited by human, male, >44 y/o, RCT = 417+1, 19 of which met inclusion criteria of T rx >90 days, initial low / low-normal T, medically stable. • 615 Rx’d with T, 433 placebo. • All 5 Prostate events OR = 1.78 (1.07-2.95) • None individually significant, strongest trend = Bx • Prostate cancer (PSA>4 & +Bx) OR 1.09 (0.49 – 2.49) • HCT > 50% OR 3.69 (1.82-7.51) • CV, OSA, death = not statistically different with trend for lower CV events (ex. Arrhythmia) and deaths • N = 85,862 to detect 20%  p CA for 1 year • So IoM recommends short term efficacy trials as next step

  36. Monitoring Guideline NEJM 2004;350:488 ? lipids

  37. If the PSA rises

  38. What to do until the evidence is in? • Stringent diagnostic criteria • 3 early AM total * T’s < 200 ng/dl • High LH = primary hypogonadism • NL or low LH = secondary hypogonatism • √ Serum TSH, fT4, cortisol, prolactin, & MRI brain/sella • Rx T only if above criteria met. • If T Rx, monitor serum T & sx • Goal: ? young men’s normal 500-700 vs. • Goal: ? older men’s normal 300-450 ng/dl (“prudent”) • Screen & Monitor for adverse risk & outcomes • See previous slides NEJM 2004;350:482-492, 440-442, & 2004-2006.

  39. Rx: androgen (Class III 1991) • Testosterone cipionate, 200 mg/ml./2 wk • 200 mg/ml, 10 ml. vial, $88.99, = $ 18 / month * $65.42 /ml+ • Testosterone enanthate, 200 mg/ml/2wk • * not listed $44.78 / ml+ • Testosterone topical, 5-10 gm / am • 1% gel, @ 5 gm / day = $ 210-230 / month * • Androgel and Testim $227.75/ mo+ • Testosterone transdermal patch • 2.5 – 10 mg. qhs, @ 5 mg/d “Androderm” $223.03 / mo+ ”Testaderm” $112.29 / mo + • Testosterone, oral, methyltestosterone & fluoxymesterone • Erratic absorption, less effective, cholestasis • 10-50 mg. po / day - @ 20 mg/d = $187 / month * NA • Testosterone buccal, 30 mg. q 12 h • 30 mg., #60 = $222.42, = $ 220 / month * “Striant” $213.20 / mo+ • Testosterone pellets, injected SQ, NA • 75 mg/pellet, 3-6 / 3-6 mos., “Testopel” $160 + $20/pellet + visit • 100 mg & 200 mg pellets compounded by some pharmacies * Epocrates, Drug Store.com prices + Price, UWH pharmacy

  40. Tests Available at UWH • Testosterone, Total • Testosterone Free, Adult Male * • Testosterone, Bio-available and Sex Hormone Binding Globulin, Adult Male • 5-a-Dihydrotestosterone • * ARUP uses RAI measurement adjusted by a complex formula including measures of albumin and sex hormone binding globulin and known binding constants. The R2 = 0.94 when compared to Endocrine Science’s equilibrium dialysis method. The unreliable RAI test is a direct measurement, unadjusted.

  41. ILOsIntended Learning Outcomesa.k.a., Learning Objectives • Androgen physiology • Androgen changes with aging • Syndrome of ADAM • Effects of testosterone replacement • Practice guideline

  42. Bonus factoid

  43. Licorice  Testosterone NEJM 1999;341:1158

  44. The lecture ends here! Questions? Answers $0.25Answers requiring thought $1.00Correct answers $2.50 Comments?

  45. If you want to read more … • Liverman CT, Blazer DG, eds. Testosterone and aging: clinical research directions. Washington, D.D.: National Academies Press, 2004. (IoM report) • Laumann EO, PaikA, Rosen RC. Sexual dysfunction in the US: prevalence and predictors. JAMA 1999;281:537-44. Correction 281:1174. • Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. NEJM 2004;350:482-92. • Calof OM, Singh AB, Martin LL, et.al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. Journal of Gerontology 2005;11:1451-1457. • Full bibliography available on request: nmj@medicine.wisc.edu

More Related